One Federal Agency’s Crusade Against Patent Litigation Settlements
Cross-posted at Forbes.com’s “On the Docket” blog Patent litigation has become a necessary, and expensive, precursor to the release of new generic drugs. Rather than incur millions in litigation costs, branded and generic companies often prefer to settle. Occasionally, the settlement terms include a payment from the generic to the branded company, along with an agreement that the generic drug … Continued